Skip to main content

Table 1 Demographics and pre-existing comorbidities in non-transplant and transplant patients with NDMM by LOT

From: Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

  Non-transplant Transplant
Characteristic Non-transplant overall
N = 22,062
By use of LOT   Transplant overall
N = 2763
By use of LOT   Frontline induction therapy Frontline induction therapy by use of consolidation therapya Frontline induction therapy
> 1 LOT
n = 9505
Only 1 LOT
n = 12,557
P-valueb > 1 LOT
n = 2184
Only 1 LOT
n = 579
P-valueb Yes
n = 1682
Yes
n = 187
No
n = 1495
No
n = 1081
Age at MM diagnosis, years
 Mean (SD) 71.1 (10.4) 70.4 (10.1) 71.6 (10.6) < 0.0001 62.3 (8.7) 62.3 (8.6) 62.4 (9.0) 0.6397 62.9 (8.6) 61.0 (9.1) 63.1 (8.5) 61.4 (8.8)
 Median (Q1–Q3) 72.0 (65.0–79.0) 72.0 (65.0–78.0) 73.0 (65.0–80.0) < 0.0001 65.0 (57.0–69.0) 64.0 (57.0–69.0) 65.0 (57.0–69.0) 0.3294 65.0 (58.0–69.0) 62.0 (55.0–68.0) 65.0 (58.0–69.0) 63.0 (56.0–68.0)
 Min, max 20, 100 23, 95 20, 100   27, 82 27, 82 31, 80   27, 82 37, 80 27, 82 28, 80
Age categories, n (%)     < 0.0001     0.7143     
 < 65 5197 (23.6) 2304 (24.2) 2893 (23.0)   1378 (49.9) 1094 (50.1) 284 (49.1)   781 (46.4) NR NR 597 (55.2)
 65–74 7741 (35.1) 3581 (37.7) 4160 (33.1)   1298 (47.0) 1019 (46.7) 279 (48.2)   840 (49.9) 74 (40) 766 (51) 458 (42.4)
 75–84 7536 (34.2) 3174 (33.4) 4362 (34.7)   87 (3.1) 71 (3.3) 16 (2.8)   61 (3.6) NR NR 26 (2,4)
 ≥ 85 1588 (7.2) 446 (4.7) 1142 (9.1)   
Male, n (%) 11,097 (50.3) 4731 (49.8) 6366 (50.7) 0.1745 1556 (56.3) 1249 (57.2) 307 (53.0) 0.0723 927 (55.1) 110 (59) 817 (55) 629 (58.2)
Race, n (%)c     < 0.0001     < 0.0001     
 White 13,176 (59.7) 5847 (61.5) 7329 (58.4)   1263 (45.7) 1069 (48.9) 194 (33.5)   709 (42.2) 130 (70) 579 (39) 554 (51.2)
 Black 2901 (13.1) 1269 (13.4) 1632 (13.0)   252 (9.1) 203 (9.3) 49 (8.5)   128 (7.6) 25 (13) 103 (7) 124 (11.5)
 Asian 428 (1.9) 205 (2.2) 223 (1.8)   26 (0.9) NR NR   NR NR NR NR
 Hispanic 225 (1.0) 108 (1.1) 117 (0.9)   NR NR NR   NR NR NR NR
 Unknown/other 5332 (24.2) 2076 (21.8) 3256 (25.9)   1207 (43.7) 880 (40.3) 327 (56.5)   821 (48.8) 29 (16) 792 (53) 386 (35.7)
Charlson Comorbidity Index
 Mean (SD) 1.5 (1.8) 1.4 (1.7) 1.5 (1.8) 0.0065 1.2 (1.5) 1.1 (1.4) 1.3 (1.7) 0.0306 1.2 (1.5) 0.8 (1.5) 1.3 (1.5) 1.1 (1.4)
 Median (Q1–Q3) 1.0 (0–2.0) 1.0 (0–2.0) 1.0 (0–2.0) 0.5335 1.0 (0–2.0) 1.0 (0–2.0) 1.0 (0–2.0) 0.2183 1.0 (0–2.0) 0.0 (0–1.0) 1.0 (0–2.0) 0.0 (0–2.0)
 Min, max 0, 13 0, 12 0, 13   0, 11 0, 10 0, 11   0, 11 0, 8 0, 11 0, 10
Comorbidities during 180 days prior to start of first LOT, n (%)
 Any comorbidity below 14,539 (65.9) 6164 (64.9) 8375 (66.7) 0.0042 1638 (59.3) 1261 (57.7) 377 (65.1) 0.0013 1051 (62.5) 82 (44) 969 (65) 587 (54.3)
 Cardiac arrhythmia 4327 (19.6) 1627 (17.1) 2700 (21.5) < 0.0001 294 (10.6) 232 (10.6) 62 (10.7) 0.9528 182 (10.8) 16 (9) 166 (11) 112 (10.4)
 Congestive heart failure 2984 (13.5) 1008 (10.6) 1976 (15.7) < 0.0001 117 (4.2) 95 (4.3) 22 (3.8) 0.5589 63 (3.7) NR NR 54 (5.0)
 Hypertension, complicated 3718 (16.9) 1382 (14.5) 2336 (18.6) < 0.0001 260 (9.4) 177 (8.1) 83 (14.3) < 0.0001 165 (9.8) NR NR 95 (8.8)
 Hypertension, simple 11,698 (53.0) 5059 (53.2) 6639 (52.9) 0.6022 1316 (47.6) 1016 (46.5) 300 (51.8) 0.0234 847 (50.4) 62 (33) 785 (53) 469 (43.4)
 Hepatic disease 972 (4.4) 388 (4.1) 584 (4.7) 0.0415 151 (5.5) 102 (4.7) 49 (8.5) 0.0004 104 (6.2) NR NR 47 (4.3)
 Pulmonary circulation disorders 1027 (4.7) 348 (3.7) 679 (5.4) < 0.0001 56 (2.0) 39 (1.8) 17 (2.9) 0.0807 32 (1.9) NR NR 24 (2.2)
 Renal impairment 5317 (24.1) 2083 (21.9) 3234 (25.8) < 0.0001 471 (17.0) 352 (16.1) 119 (20.6) 0.0116 298 (17.7) 23 (12) 275 (18) 173 (16.0)
 Valvular disease 2258 (10.2) 887 (9.3) 1371 (10.9) 0.0001 158 (5.7) 119 (5.4) 39 (6.7) 0.2357 92 (5.5) NR NR 66 (6.1)
  1. LOT Line of therapy, MM Multiple myeloma, NDMM Newly diagnosed multiple myeloma, NR Not reported, Q Quartile, SD Standard deviation
  2. Values of 1–10 have not been reported to conform to the Centers for Medicare and Medicaid Services cell size suppression policy; Similarly, data have not been reported for categorical variables and by subgroup to avoid making it possible to calculate the values of the NR cells
  3. aConsolidation therapy was evaluated among patients with NDMM who received frontline induction therapy, and was required to have been ongoing for ≥1 month after ASCT
  4. bP-value vs. > 1 LOT; P-values were computed using chi-squared tests for categorical variables and t-tests for continuous variables
  5. cRace data were not available in the OPTUM™ Commercial Claims database for patients who received transplant
\